[Anti-leukotriene therapy of patients with allergic rhinosinusitis and bronchial asthma].
The authors review current knowledge on pathogenesis of allergic rhinosinusitis and bronchial asthma and their relations, show the role of leukotriens in development of respiratory allergy, characterize antileukotrienic medicines. Eleven patients with allergic rhinosinusitis and bronchial asthma received monotherapy with zafirlucast (acolapt) which is a blocker of leukotrienic receptors. Eight patients benefited from the treatment. The positive effect consisted in improvement of nasal respiration, reduction of rhinorrhea, edema of nasal mucosa, size of polyps.
Ovchinnikov
Iu M
IuM
Ovcharenko
S I
SI
Ovchinnikov
A Iu
AIu
Chichkova
N V
NV
Gumeniuk
V A
VA
D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D048448:Phenylcarbamates; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use*
D018927:Anti-Asthmatic Agents; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; C062735:zafirlukast